Scintigraphy with 99mTc-HMPAO labeled leukocytes is still an accurate and convenient tool to rule out suspected inflammatory bowel disease in children
Abstract
BACKGROUND: Abdominal pain is a common complaint in children and its differential diagnosis includes inflammatory bowel
disease (IBD). The aim of the study was to assess the diagnostic accuracy of scintigraphy with 99mTechnetium Hexamethylpropyleneamine
Oxime (99mTc-HMPAO) labeled leukocytes in children with suspected IBD.
MATERIAL AND METHODS: Eighty-five children (age 12.4 ± 4.3 years, 47% boys) with suspected IBD based on clinical presentation, laboratory and ultrasound findings underwent scintigraphy with 99mTc-HMPAO labeled leukocytes. Abdominal scintigrams were acquired 40 min and 90 min post injection, and whole body scintigrams at 180 min. Scintigraphy was evaluated by two specialists in nuclear medicine. The results were compared with the final diagnosis established by endoscopy, histology, other imaging methods, and follow-up evaluated by an expert in pediatric gastroenterology.
RESULTS: Scintigraphy results corresponded with the final diagnosis in 78 (91%) patients resulting in a sensitivity of 89% (95%CI 72 to 98%), specificity of 91% (95% CI 82 to 98%), and accuracy of 91% (95% CI 83 to 96%). The interobserver agreement was 0.82 (95% CI 0.75 to 0.88) and the radiation dose estimate was 4.2 ± 1.5 mSv. In 28 children (25 positives and 3 negatives on scintigraphy), the diagnosis of IBD was established by endoscopy, histology, MR enterography, or fluoroscopy. Five positive findings on scintigraphy were not confirmed by other methods or during follow-up.
CONCLUSION: Scintigraphy with 99mTc-HMPAO labeled leukocytes in children with suspected IBD has high accuracy and offers a non-invasive option for detecting the presence of gastrointestinal inflammation. Scintigraphy is a powerful non-invasive decision-making tool in the management of suspected IBD that may spare a greater proportion of children of more invasive and demanding examinations.
Keywords: scintigraphy99mTc-HMPAOleukocyteinflammatory bowel disease
References
- McFerron BA, Waseem S. Chronic recurrent abdominal pain. Pediatr Rev. 2012; 33(11): 509–517.
- Clouse RE, Mayer EA, Aziz Q, et al. Functional abdominal pain syndrome. Gastroenterology. 2006; 130(5): 1492–1497.
- Di Lorenzo C, Colletti RB, Lehmann HP, et al. Chronic Abdominal Pain in Children: A Clinical Report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenerol Nutr. 2008; 40: 245–248.
- Oostenbrink R, Jongman H, Landgraf JM, et al. Functional abdominal complaints in pre-school children: parental reports of health-related quality of life. Qual Life Res. 2010; 19(3): 363–369.
- Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015; 50: 942–951.
- Benchimol E, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011; 17: 423–439.
- Müller KE, Lakatos PL, Arató A, et al. Hungarian IBD Registry Group (HUPIR). Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013; 57(5): 576–582.
- Levine YY, Koletzko J, Turner D, et al. European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014; 58(6): 795–806.
- Duricova D, Fumery M, Annese V, et al. The natural history of Crohn's disease in children: a review of population-based studies. Eur J Gastroenterol Hepatol. 2017; 29(2): 125–134.
- Ruemmele FM, Veres G, Kolho KL, et al. European Crohn's and Colitis Organisation, European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8(10): 1179–1207.
- Gionchetti P, Dignass A, Danese S, et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017; 11(1): 3–25.
- Turner D, Levine A, Escher JC, et al. European Crohn's and Colitis Organization, European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012; 55(3): 340–361.
- Treves ST. Pediatric Nuclear Medicine and Molecular Imaging. Springer 2014: 552–556.
- Catalano O, Maccioni F, Lauri Ch, et al. Hybrid Imaging in Crohn´s disease: from SPECT/CT to PET/MR and new image interpretation criteria. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2018; 62: 40–55.
- Mentzel HJ, Reinch S, Kurzai M, et al. Magnetic resonance imaging in children and adolescents with chronic inflammatory bowel disease. World J Radiol. 2014; 20: 1180–1191.
- Cheow HK, Voutnis DD, Evans W, et al. Quantification of Disease Activity in Patients Undergoing Leukocyte Scintigraphy for Suspected Inflammatory Bowel Disease. Eur J Nucl Med Mol Imag. 2005; 12: 329–337.
- Challa S, Lyons KP, Broekelschen P, et al. Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn disease and steroid use. Clin Nucl Med. 1997; 22(10): 700–703.
- Peters AM. The utility of [99mTc]HMPAO-leukocytes for imaging infection. Semin Nucl Med. 1994; 24(2): 110–127.
- Charron M, Charron M, Orenstein SR, et al. Detection of inflammatory bowel disease in pediatric patients with technetium-99m-HMPAO-labeled leukocytes. J Nucl Med. 1994; 35(3): 451–455.
- Chroustová D, Volf V, Kleisner I, et al. 99mTcHMPAO-Labelled Leukocytes Scintigraphy in Monitoring Children and Adolescents with IBD. Curr Radiopharm. 2009; 2: 18–23.
- Papós M, Várkonyi A, Láng J, et al. HM-PAO-labeled leukocyte scintigraphy in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996; 23(5): 547–552.
- Stathaki MI, Koukouraki SI, Karkavitsas NS, et al. Role of scintigraphy in inflammatory bowel disease. World J Gastroenterol. 2009; 15(22): 2693–2700.
- Papós M, Várkonyi A, Láng J, et al. HM-PAO-labeled leukocyte scintigraphy in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996; 23(5): 547–552.
- Lantto EH, Lantto TJ, Vorne M. Fast diagnosis of abdominal infections and inflammations with technetium-99m-HMPAO labeled leukocytes. J Nucl Med. 1991; 32(11): 2029–2034.
- Javadi H, Amiriani T, Mirkarimi H, et al. Scintigraphy with 99mTc(V)-DMSA in monitoring patients with inflammatory bowel disease. Hell J Nucl Med. 2013; 16(3): 209–212.
- Martínez-Rodríguez I, Carril JM. [Update on the use of PET radiopharmaceuticals in inflammatory disease]. Rev Esp Med Nucl Imagen Mol. 2013; 32(6): 378–386.
- Caobelli F, Evangelista L, Quartuccio N, et al. Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. World J Radiol. 2016; 8(10): 829–845.
- Malham M, Hess S, Nielsen RG, et al. PET/CT in the diagnosis of inflammatory bowel disease in pediatric patients: a review. Am J Nucl Med Mol Imaging. 2014; 4(3): 225–230.
- Catalano OA, Wu V, Mahmood U, et al. Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nucl Med Mol Imaging. 2018; 8(1): 62–69.
- Pellino G, Nicolai E, Catalano OA, et al. PET/MR versus PET/CT imaging impact on the clinical management of small-bowel Crohn´s disease. Radiology. 2015; 278: 792–800.
